HOME >> OTHER ACTIVITIES » TECHNOLOGICAL TRANSFER
MIT-Engineered Peptide Targets COVID-19
29/06/2020 TECHNOLOGICAL TRANSFER 90
 
MIT-Engineered Peptide Targets COVID-19
ISAAA News - June 24, 2020
 
 
Figure: Colorized scanning electron micrograph of an apoptotic cell (pink) heavily infected with SARS-COV-2 virus particles (green). MIT researchers are using computational models of protein interactions to design a peptide that can bind to coronavirus proteins and shuttle them into a cellular pathway that breaks them down. Photo Source: National Institute of Allergy and Infectious Diseases/NIH
 
Using computational models of protein interactions, researchers at the Massachusetts Institute of Technology Media Lab and Center for Bits and Atoms have designed a peptide that binds to coronavirus proteins and shuttles them into a cellular pathway that breaks them down. The researchers say this peptide has potential as a treatment that would prevent the SARS-CoV-2 virus from reproducing itself within infected cells.
 
Scientists from all over the world are pursuing many different strategies to develop new therapeutics against SARS-CoV-2, the coronavirus that causes COVID-19. One area of interest is developing antibodies that bind to and inactivate viral proteins such as the spike protein, which coronaviruses use to enter human cells. A related approach uses small protein fragments called peptides instead of antibodies.
 
The MIT team set out to engineer peptides that could strongly bind to the spike protein inside cells, and to use these peptides to trigger the cells to break down the viral proteins. They used a computational model of protein interactions that they had previously trained to optimize binding strength between two proteins. They then used their model to break ACE2 into many small fragments. The process generated about 25 candidate peptides, from which they found the best candidate, a 23-amino-acid peptide which broke down about 20 percent of the RBD proteins in the cells. To further improve the peptide's performance, the researchers used their model to simulate how its receptor-binding domain would be affected if they substituted different amino acids at each of its 23 positions. That optimization process yielded a mutant peptide that improved the degradation rate to over 50 percent.

For more details, read the article on MIT News.

 

 

OLDER NEWS
Video Clip
Visitors counter
số người truy cậpsố người truy cậpsố người truy cậpsố người truy cậpsố người truy cậpsố người truy cậpsố người truy cập
số người truy cậpToday:27
số người truy cậpYesterday:288
số người truy cậpThis week:27
số người truy cậpThis month:27
số người truy cậpAll:509126
số người truy cậpOnline:12